Castle Biosciences, Inc. - Common stock (CSTL)

Castle Biosciences' bullish structure is strengthening as momentum builds ahead of a possible breakout.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.

Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.

On Tuesday, Sotera Health stock hit a key technical milestone, with its Relative Strength Rating climbing to 91, up from 86 the day before.

Let's have a look at the gap up and gap down stocks in today's session.

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Castle Biosciences (CSTL) Q2 2025 earnings beat estimates with $86.19M revenue & $0.15 EPS, driving a 6% after-hours surge. Strong test volume growth fuels optimism.

On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83.

It is more of a stock pickers market than usual as momentum factors are currently exaggerated.